First Study Explores Safety and Effects of NNC0480-0389 with Semaglutide
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
Background
Semaglutide, a widely used GLP-1 receptor agonist (a class of drugs that mimic the action of glucagon-like peptide-1, a hormone involved in blood sugar regulation and appetite), has proven effective in managing type 2 diabetes and obesity by improving glycemic control and promoting weight loss. While its benefits are well-established, there's a growing interest in combination therapies to enhance efficacy or address specific metabolic pathways. This Phase 1 study was the first to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NNC0480-0389 when administered alone and in combination with semaglutide.